Managers / Q1 2022 · view latest →
Krensavage Asset Management, LLC
CIK 0001609251 · 610 FIFTH AVENUE, SUITE 301, NEW YORK, NY, 10020 · 212-888-1582
Summary
Krensavage Asset Management, LLC reported $290M in U.S.-listed holdings across 13 positions for Q1 2022.
Its largest position, REGN, represents 16.1% of the portfolio.
Compared with Q4 2021, the fund opened 3 new positions and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 91.6% · $266M
- Other · 8.4% · $25M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| KODKODIAK SCIENCES INC | NEW | +450.6K | 450.6K | +$3M | $3M |
| CAHCARDINAL HEALTH INC | NEW | +13.2K | 13.2K | +$748,000 | $748,000 |
| ASSEMBLY BIOSCIENCES INC | NEW | +10.1K | 10.1K | +$21,000 | $21,000 |
| MCKMCKESSON CORP | TRIMMED | −32.3K | 124.2K | −$871,000 | $38M |
| BIIBBIOGEN INC | ADDED | +8.3K | 111.4K | −$1M | $23M |
| EGRXEAGLE PHARMACEUTICALS INC | ADDED | +8.3K | 114.8K | +$259,000 | $6M |
| TARO PHARMACEUTICAL INDUS | ADDED | +27.0K | 566.0K | −$3M | $24M |
| REGNREGENERON PHARMACEUTICALS | HELD | −2.2K | 66.9K | +$3M | $47M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | REGNREGENERON PHARMACEUTICALShistory → | COM | 16.10% | $47M | 66.9K |
| 2 | ENTAENANTA PHARMACEUTICALS INChistory → | COM | 13.46% | $39M | 548.8K |
| 3 | MCKMCKESSON CORPhistory → | COM | 13.10% | $38M | 124.2K |
| 4 | ALKSALKERMES PLChistory → | COM | 12.92% | $37M | 1.42M |
| 5 | UTHRUNITED THERAPEUTICS CORPhistory → | COM | 12.47% | $36M | 201.6K |
| 6 | EXELEXELIXIS INChistory → | COM | 11.96% | $35M | 1.53M |
| 7 | TARO PHARMACEUTICAL INDUS | COM | 8.44% | $24M | 566.0K |
| 8 | BIIBBIOGEN INChistory → | COM | 8.08% | $23M | 111.4K |
| 9 | EGRXEAGLE PHARMACEUTICALS INChistory → | COM | 1.96% | $6M | 114.8K |
| 10 | KODKODIAK SCIENCES INChistory → | COM | 1.20% | $3M | 450.6K |
| 11 | CAHCARDINAL HEALTH INC | COM | 0.26% | $748,000 | 13.2K |
| 12 | NEXTCURE INC | COM | 0.05% | $149,000 | 30.6K |
| 13 | ASSEMBLY BIOSCIENCES INC | COM | 0.01% | $21,000 | 10.1K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $256M | 20 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $283M | 18 | Feb 18, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $235M | 17 | Nov 17, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $189M | 15 | Aug 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $181M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $169M | 12 | Feb 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2024 | $178M | 13 | Nov 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $218M | 13 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $226M | 12 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $282M | 12 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $272M | 12 | Nov 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $316M | 12 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $329M | 12 | May 16, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $324M | 12 | Feb 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $314M | 14 | Nov 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $302M | 14 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $290M | 13 | May 17, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $288M | 10 | Feb 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $319M | 13 | Nov 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $295M | 13 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $289M | 12 | May 18, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $342M | 12 | Feb 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $314M | 11 | Dec 8, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $368M | 11 | Aug 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2020 | $311M | 13 | May 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $293M | 12 | Feb 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $260M | 10 | Nov 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $308M | 10 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $370M | 12 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.